For the treatment of T2D, most patients received metformin (77/117, 65.8%), followed by sulphonyl urea (31/117, 26.5%), SGLT-2 inhibitor (17/117, 14.5%), DPP-4 inhibitor (6/117, 5.1%), and GLP-1 agonist (3/117, 2.6%). The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.